Comparisons of ORs for longitudinal changes in QOL and function >2 y compared with baseline values in recipients of less-intensive vs intensive initial therapies
| QOL and function by AML-CM . | OR . | 95% CI . | P . |
|---|---|---|---|
| Better FACT-G (>mean ± SD) | |||
| 4-6 | 2.33 | 1.06-5.00 | .04 |
| 7-9 | 1.56 | 0.76-3.23 | .22 |
| ≥10 | 1.45 | 0.64-3.23 | .38 |
| Better EQ-5D (>33rd percentile) | |||
| 4-6 | 1.64 | 0.80-3.33 | .18 |
| 7-9 | 1.67 | 0.82-3.45 | .16 |
| ≥10 | 0.63 | 0.31-1.25 | .18 |
| Better PHQ9 (score <10) | |||
| 4-6 | 1.75 | 0.76-4.00 | .19 |
| 7-9 | 1.33 | 0.60-2.94 | .48 |
| ≥10 | 1.37 | 0.66-2.78 | .40 |
| Better IADL (score, 14) | |||
| 4-6 | 1.11 | 0.62-2.00 | .72 |
| 7-9 | 1.08 | 0.63-1.89 | .79 |
| ≥10 | 0.45 | 0.16-1.25 | .13 |
| Better ADL (score, 14) | |||
| 4-6 | 0.72 | 0.36-1.45 | .36 |
| 7-9 | 1.23 | 0.67-2.27 | .50 |
| ≥10 | 0.8 | 0.39-1.64 | .54 |
| Better walk test (≥0.8 m/sec) as marker of frailty | |||
| 4-6 | 0.96 | 0.39-2.33 | .93 |
| 7-9 | 0.67 | 0.33-1.35 | .27 |
| ≥10 | 0.45 | 0.20-1.01 | .05 |
| QOL and function by AML-CM . | OR . | 95% CI . | P . |
|---|---|---|---|
| Better FACT-G (>mean ± SD) | |||
| 4-6 | 2.33 | 1.06-5.00 | .04 |
| 7-9 | 1.56 | 0.76-3.23 | .22 |
| ≥10 | 1.45 | 0.64-3.23 | .38 |
| Better EQ-5D (>33rd percentile) | |||
| 4-6 | 1.64 | 0.80-3.33 | .18 |
| 7-9 | 1.67 | 0.82-3.45 | .16 |
| ≥10 | 0.63 | 0.31-1.25 | .18 |
| Better PHQ9 (score <10) | |||
| 4-6 | 1.75 | 0.76-4.00 | .19 |
| 7-9 | 1.33 | 0.60-2.94 | .48 |
| ≥10 | 1.37 | 0.66-2.78 | .40 |
| Better IADL (score, 14) | |||
| 4-6 | 1.11 | 0.62-2.00 | .72 |
| 7-9 | 1.08 | 0.63-1.89 | .79 |
| ≥10 | 0.45 | 0.16-1.25 | .13 |
| Better ADL (score, 14) | |||
| 4-6 | 0.72 | 0.36-1.45 | .36 |
| 7-9 | 1.23 | 0.67-2.27 | .50 |
| ≥10 | 0.8 | 0.39-1.64 | .54 |
| Better walk test (≥0.8 m/sec) as marker of frailty | |||
| 4-6 | 0.96 | 0.39-2.33 | .93 |
| 7-9 | 0.67 | 0.33-1.35 | .27 |
| ≥10 | 0.45 | 0.20-1.01 | .05 |
Comparisons stratified according to AML-CM score 4-6, 7-9, and ≥10. No comparisons were performed for patients with AML-CM score ≤3 because all received intensive therapies. Odds ratio (OR) comparisons are both unadjusted and adjusted for undergoing allogeneic HCT as time-dependent covariate. Higher OR means better outcomes for less-intensive therapies; lower OR means worse outcomes for less-intensive therapies.
ADL, activities of daily living; EQ5D, EuroQoL 5-dimensional health-related quality of life assessment; FACT-G, Functional Assessment of Cancer Therapy–General; IADL, instrumental activities of daily living; PHQ-9, Patient Health Questionnaire-9.